Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS).
Beaudart, Charlotte; Bauer, Jürgen M.; Landi, Francescoet al.
2021 • In Aging Clinical and Experimental Research, 33, p. 1079-1083
[en] BACKGROUND AND AIMS: To assess experts' preference for sarcopenia outcomes. METHODS: A discrete-choice experiment was conducted among 37 experts (medical doctors and researchers) from different countries around the world. In the survey, they were repetitively asked to choose which one of two hypothetical patients suffering from sarcopenia deserves the most a treatment. The two hypothetical patients differed in five pre-selected sarcopenia outcomes: quality of life, mobility, domestic activities, fatigue and falls. A mixed logit panel model was used to estimate the relative importance of each attribute. RESULTS: All sarcopenia outcomes were shown to be significant, and thus, important for experts. Overall, the most important sarcopenia outcome was falls (27%) followed by domestic activities and mobility (24%), quality of life (15%) and fatigue (10%). DISCUSSION AND CONCLUSION: Compared to patient's preferences, experts considered falls as a more important outcome of sarcopenia, while the outcomes fatigue and difficulties in domestic activities were considered as less important.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bauer, Jürgen M.
Landi, Francesco
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Hiligsmann, Mickael
Language :
English
Title :
Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS).
Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. 10.1093/ageing/afy169 DOI: 10.1093/ageing/afy169
Beaudart C, Zaaria M, Pasleau F et al (2017) Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS ONE 12:e0169548. 10.1371/journal.pone.0169548 DOI: 10.1371/journal.pone.0169548
Hiligsmann M, Beaudart C, Bruyère O et al (2019) Outcome priorities for older persons with sarcopenia. J Am Med Dir Assoc. 10.1016/j.jamda.2019.08.026 DOI: 10.1016/j.jamda.2019.08.026
Harrison M, Milbers K, Hudson M et al. (2017) Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. BMJ Open. doi: 10.1136/bmjopen-2016-014719 DOI: 10.1136/bmjopen-2016-014719
Johnson FR, Hauber AB, Özdemir S et al (2010) Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. J Manag Care Pharm 16:616–628. 10.18553/jmcp.2010.16.8.616 DOI: 10.18553/jmcp.2010.16.8.616
Beaudart C, Bruyère O, Cruz-Jentoft AJ et al (2019) Patient’s engagement in the identification of critical outcomes in Sarcopenia. J Am Med Dir Assoc. 10.1016/j.jamda.2019.09.004 DOI: 10.1016/j.jamda.2019.09.004
Clegg DO, Reda DJ, Harris CL et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795–808 DOI: 10.1056/NEJMoa052771
Hartholt KA, Van Beeck EF, Polinder S et al (2011) Societal consequences of falls in the older population: Injuries, healthcare costs, and long-term reduced quality of life. J Trauma—Inj Infect Crit Care 71:748–753. 10.1097/TA.0b013e3181f6f5e5 DOI: 10.1097/TA.0b013e3181f6f5e5
Ahmed T, Curcio CL, Auais M et al (2020) Falls and life-space mobility: longitudinal analysis from the international mobility in aging study. Aging Clin Exp Res. 10.1007/s40520-020-01540-0 DOI: 10.1007/s40520-020-01540-0
Beaudart C, Biver E, Bruyère O et al (2018) Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res 30:413–418. 10.1007/s40520-017-0794-8 DOI: 10.1007/s40520-017-0794-8
Musich S, Wang SS, Ruiz J et al (2018) The impact of mobility limitations on health outcomes among older adults. Geriatr Nurs (Minneap) 39:162–169. 10.1016/j.gerinurse.2017.08.002 DOI: 10.1016/j.gerinurse.2017.08.002
Reginster JY, Beaudart C, Al-Daghri N, et al (2021) Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clin Exp Res 33:3–17. 10.1007/s40520-020-01663-4
de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA (2015) Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient—Patient-Centered Outcomes Res 8:373–384. 10.1007/s40271-015-0118-z DOI: 10.1007/s40271-015-0118-z
